Susquehanna International Group, LLP Summit Therapeutics Inc. Transaction History
Susquehanna International Group, LLP
- $823 Billion
- Q3 2025
A detailed history of Susquehanna International Group, LLP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 246,562 shares of SMMT stock, worth $4.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
246,562
Previous 299,973
17.81%
Holding current value
$4.5 Million
Previous $6.38 Million
19.93%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding SMMT
# of Institutions
261Shares Held
93.5MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...